Aethlon Medical to Webcast Biodefense Treatment Update on January 25th at 4 P.M. EST
Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that its Chairman and CEO, James A. Joyce, will host a webcast presentation on Thursday, January 25th, at 4 p.m. Eastern Time (1:00 p.m. Pacific Time). Mr. Joyce will provide a detailed corporate update, including a progress report on the Aethlon HemopurifierTM as a broad-spectrum treatment countermeasure against biological weapons. The investing public and media are invited to access the presentation online at: www.aethlonmedical.com/webcast/jan07
About Aethlon Medical
Aethlon Medical has developed a first-in-class medical device to treat infectious disease. The device, known as the HemopurifierTM, is a broad-spectrum treatment countermeasure against drug- and vaccine-resistant bioweapons; naturally evolving pandemic threats such as H5N1 Avian Flu; and chronic infectious disease targets, including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher Frost & Sullivan awarded the HemopurifierTM the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second-generation HemopurifierTM that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the HemopurifierTM technology can be found at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.